Aethlon Medical (NASDAQ:AEMD) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Aethlon Medical (NASDAQ:AEMD) announced its earnings results on Thursday. The medical equipment provider reported ($4.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.92) by ($0.10), FiscalAI reports.

Here are the key takeaways from Aethlon Medical’s conference call:

• Positive Sentiment: Aethlon has entered the final cohort of its Australian oncology trial, with only two additional participants needed if no further safety events occur; the company targets completion of treatments and follow-up by year-end 2026 or early 2027.
• Positive Sentiment: Preliminary, unstatistical analyses from cohort 2 showed more consistent and longer-lasting reductions in extracellular vesicles and cancer-related microRNAs, along with favorable directional changes in lymphocyte subsets and immunotherapy-related laboratory ratios than in cohort 1.
• Neutral Sentiment: Preclinical research found that the Hemopurifier’s resin can bind extracellular vesicles in long COVID samples and reduce certain inflammation- and immune-dysregulation-associated microRNAs; the company is evaluating potential clinical paths and additional work in lupus and heart disease related to chronic kidney disease.
• Positive Sentiment: Cash and cash equivalents totaled approximately $4.9 million at quarter-end, and a subsequent public offering raised about $4 million in gross proceeds; management believes current resources can fund operations for at least 12 months, while quarterly operating expenses declined 11.9% year over year to approximately $1.6 million.

Aethlon Medical Price Performance

Shares of Aethlon Medical stock traded down $0.11 on Thursday, reaching $2.93. 19,564 shares of the company traded hands, compared to its average volume of 63,320. The company has a 50 day moving average of $5.12 and a 200 day moving average of $8.91. Aethlon Medical has a 52 week low of $2.63 and a 52 week high of $137.00. The firm has a market capitalization of $1.90 million, a PE ratio of -0.04 and a beta of 1.41.

Hedge Funds Weigh In On Aethlon Medical

A hedge fund recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC bought a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical at the end of the most recent reporting period. Institutional investors own 1.99% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on AEMD. Wall Street Zen raised shares of Aethlon Medical to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research report on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce”.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.